{"@id":"https://bioecon.ru/technology/radioligand-therapy/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://cn.bioecon.ru/technology/radioligand-therapy/","json":"https://cn.bioecon.ru/api/v1/technology/radioligand-therapy/index.json"},"id":"radioligand-therapy","industries":["pharma","biomanufacturing"],"lang":"cn","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/johnson-johnson/","https://bioecon.ru/companies/astrazeneca/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/cryoport-systems/","https://bioecon.ru/companies/zero-cow-factory/","https://bioecon.ru/companies/21st-bio/","https://bioecon.ru/companies/pbs-biotech/","https://bioecon.ru/companies/minicircle/","https://bioecon.ru/companies/anft-association-of-nature-forest-therapy/"]},"maturity":7,"name":"靶向放射性核素配体疗法（RLT，²¹²Pb/¹⁶¹Tb）","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"高稳定性双功能大环螯合剂配位"},{"n":2,"title":"温和短寿命医用同位素高效放射标记"},{"n":3,"title":"微剂量学与单细胞尺度DNA致死破坏"},{"n":4,"title":"前沿难治性实体瘤临床转化确证"}],"summary":"通过将靶向小分子、多肽或抗体与高线性能量传递（LET）的α粒子放射性同位素（铅-212、锕-225）或新型β/俄歇电子放射源（铽-161、镥-177）精密偶联，在细胞尺度直接诱发致死性DNA双链断裂的精准核素靶向抗肿瘤疗法。","url":"/technology/radioligand-therapy/","verified":"2026-11-22"}